Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

470.28 -3.50 (-0.74%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 708,684
Open 477.52
Bid (Size) 468.00 (1)
Ask (Size) 479.00 (5)
Prev. Close 473.78
Today's Range 466.01 - 477.52
52wk Range 335.82 - 486.43
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
Eli Lilly is a good stock to buy, but these should be even better. 
Via The Motley Fool
3 Top-Rated Gene Editing Stocks Actually Making Money
Profitable gene editing stocks make increasingly compelling investments as therapies commercialize this year and beyond. 
Via InvestorPlace

Performance

YTD
+14.45%
+14.45%
1 Month
+0.02%
+0.02%
3 Month
+15.04%
+15.04%
6 Month
+14.50%
+14.50%
1 Year
+35.01%
+35.01%

More News

Read More
Why the quality investor may take a look at NASDAQ:VRTX.
Via Chartmill
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Via MarketBeat
Topics ETFs
Exposures COVID-19
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today
Via Benzinga
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
Via InvestorPlace
Vertex to Announce Second Quarter 2024 Financial Results on August 1
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Breakout Biotech Stocks on Track to Double by 2032
Via InvestorPlace
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Via The Motley Fool
2 Superior Growth Stocks to Buy if You Have $1,000 Right Now
Via The Motley Fool
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:VRTX.
Via Chartmill
13 Analysts Have This To Say About Vertex Pharmaceuticals
Via Benzinga
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
2 Healthcare Stocks That Are Screaming Buys in June
Via The Motley Fool
You’ve Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.
Via InvestorPlace
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."
Via The Motley Fool
3 Biotech Stocks That Could Make Your Grandchildren Rich
Via InvestorPlace
Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
Via The Motley Fool
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
Via The Motley Fool
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Via Benzinga
3 Top Stocks I'd Buy Today and Hold Forever Without Any Hesitation
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.